DBV Technologies Stock Breaks Its €2.75 Support Ahead of Semi-Annual Results
The French biotech company is trending downwards during the session, contrary to a nearly stable SBF 120. The stock is among the largest declines of the broad index, on the eve of its semi-annual earnings release. Today's movement continues a downward trend observed since spring.
The Stock Breaks Its €2.75 Support and Trades Below Its Three Moving Averages
DBV Technologies stock is down 3.03% at €2.748 during the session, with a volume that pushes it among the largest declines in the SBF 120. The stock broke its €2.75 support during the session and remains just below, extending the bearish momentum observed for several weeks. The price is trading 3.58% below its MM20 (€2.85) and nearly 13% below its MM200 (€3.15), indicating that the selling pressure is sustained.
The RSI at 45 remains neutral, showing no extremes at this stage. Over three months, the biotech has fallen nearly 29%, although it still shows a gain of more than 60% over one year.
Semi-Annual Accounts Expected Tomorrow, in a Case Dominated by the FDA Schedule
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The decline occurs on the eve of the first semester results announcement, scheduled for July 16, 2026. This deadline focuses attention on the cash position and the progress of preparatory work for the U.S. regulatory filing. At the end of June, the company confirmed its aim to submit its biologics license application to the FDA for Viaskin Peanut in the third quarter of 2026, without requesting additional data from the Agency.
Since then, the stock price has fluctuated around the €2.75 threshold, with sharp movements: a rebound of 4% on July 8, a decline of 3.5% on July 6, and an increase of 5.5% on July 3. The technical support break of the day calls for attention on the semi-annual publication.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,6 millions de dollars
Quarterly revenue: 1,6 millions de dollars
Net income: -98 millions de dollars
Guidance from the release
DBV is a late-stage biopharmaceutical company currently in regulatory discussions with the FDA, with BLA submission anticipated in Q3 2026; the company reports cash funding into Q3 2027, indicating reliance on capital reserves and no current revenue generation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
